Braftovi cum Erbitux positivos eventus pro cancro colorectali

Curatio cancri colorectalis iaculis, BRAF V600E mutatio gene mutationis causatio cancri colorectalis Braftovi + Erbitux tandem effectus positivos consecutus est.

Colorectal cancer curatio statum

Colorectal cancer is one of the most common malignant tumors in the digestive system. In recent years, its morbidity ranks third in the world in terms of malignant tumors, and its mortality rate ranks second, which seriously threatens people’s lives and health. With the changes in the living habits and dietary structure of our nationals, the incidence of colorectal cancer has generally shown an upward trend, and has become the second highest incidence of digestive system, and the highest incidence of malignant tumors. According to relevant research statistics, the number of new cases of colorectal cancer in China is expected to exceed 521,000 in 2018, and the number of deaths is as high as 248,000.

Studiis ostenditur quod fere XV% de aegris cum metastatic colorectal cancer gene mutationes BRAF erit pauperis et deploratae. V15E mutationem est maxime communia BRAF gene mutationem. In periculo mortis, de aegris cum BRAF V600E ferox genus BRAF gene mutationem est portare bis aegroti.

Faced with such a dangerous BRAF V600E mutation metastatic colorectal cancer, the editor shares a piece of exciting good news learned recently! On April 8, 2020, Pfizer announced that the US FDA has approved Braftovi® (encorafenib, connefenib) and Erbitux® (cetuximab, cetuximab) combination therapy (Braftovi two-drug protocol) is used to treat patients with metastatic colorectal cancer (mCRC) who carry the BRAF V600E mutation. These patients have already received one or two pre-treatments. This approval also makes the Braftovi secundo medicamentorum regimen primum iaculis justo probatum FDA pro aegris cum mCRC mutationes BRAF portantibus.

Braftovi duplici ac triplici ordine Lorem significantly salvos quodammodo continuare

Ut mane December MMXIX, accepit FDA ad supplementum novum medicamento scriptor application Program medicamentis Pfizer Braftovi secundi illius dedit primatum absolute recensionem. Et hoc secundum probat est eventus et IGNIS CRC Phase III Volume iudicium.

Studium patientibus proficiebat BRAF V600E peragatur post unum alterumve mutant mCRC priori therapiae profecisse. Et septimum dicendum quod efficacia curatio consilium est salus ritica compositae cum medicamento (imperium).

Mensam I: Medicamentum consilium cuiusque coetus

Et pelagus eventus investigationis

1. salvos Medica (OS): 9.0 mensibus essent in triplici Lorem coetus

8.4 menses Lorem coetus in in dual

Est 5.4 menses potestate coetus

2.-liberum salvos esse Progressione: 4.3 mensibus essent in triplici Lorem coetus

4.2 ad duo menses Lorem coetus

Est 1.5 menses potestate coetus

3. VI mensis-superessendam rate, in triplici Lorem coetus LXXI%

LXV% Lorem coetus in in dual

Sit potestate coetus XLVII%

4. obiectiva remissio Rate (Orr) XXVI% Lorem coetus medio triplicem

LXV% Lorem coetus in in dual

Sit potestate coetus XLVII%

De pictura a sinistra tres-medicamento comparat cum regimen de raftovi OS in potestate coetus ac pictura a dextra comparat duos medicamento regimen raftovi OS cum a potestate coetus

In generali, et comparari Erbitux irinotecan diaetam ipsis, quibus curatio, medicamento regimen efficaciam, et duo in tres-medicamento regimen non alia multa, et in paucioribus latus effectus orci.

Dr. principalem Investigator Scott Kopetz ait: "et sicut antea tractata BRAF V600E mutant metastatic patientes estote ad colorectal cancer, Braftovi + Erbitux (+ conefinil cetuximab) Hoc est primum et solum targeted Lorem novum aegris talem optionem male opus curatio. '

Braftovi principiis compositum justo et indicia

Braftovi’s active pharmaceutical ingredient binmetinib is an oral small molecule BRAF inhibitor, and Mektovi’s active pharmaceutical ingredient encorafenib is an oral small molecule MEK inhibitor. MEK and BRAF are two key protein kinases in the MAPK signaling pathway (RAS-RAF-MEK-ERK).

Studies have shown that this pathway regulates many key cell activities including cell proliferation, differentiation, survival, and angiogenesis. In many cancers, such as melanoma, colorectal cancer, and thyroid cancer, proteins in this signaling pathway have been shown to be abnormally activated.

In Civitatibus Foederatis, Braftovi + Mektovi iunctura probata est melanoma irresectabile vel metastaticum cum BRAF V600E vel BRAF V600K mutationibus. Genus BRAF melanoma silvestre ad curationem Braftovi non convenit. In Europa compositum approbatur adultis cum melanoma irresectabili vel metastatico cum mutatione BRAF V600. In Iaponia, compositum approbatur pro melanoma BRAF-mutatum irresectabile.

In MMXIX NCCN Praeceptiones Colorectalis Cancer addit duas novas EGFR / BRAF / MEK compositum therapiae inhibitoris triplex aegros cum progressu BRAF V2019E mutationem positivam provectiorem morborum, scilicet:

[I] Dabrafenib + + Trametinib Cetuximab / Panitumumab (Cetuximab / Panitumumab)

[II] Encorafenib (conefinil) + Binimetinib (bimetinib) Cetuximab + / Panitumumab (cetuximab / panitumumab)

Xiaobian dicere quod non habet

In temporibus therapiae iaculis, omnis aegrotus cum cancro colorectali MSI detectio, mutatio analyseos RAS et BRAF transeat, et amplificationem HER2, NTRK et alia detectio generum, quantum fieri potest, perficiat. Genetica probatio (NGS) in magno numero examinandi initialis plerisque aegris erit. Cancer amici, qui geneticam probationem subierunt, relationem ad Dicasterii medici ad interpretationem mittere possunt si optio curatio pertinet.

Editor credit in recentius investigationis progressum et optimum medicamentum cancer colorectalis futurum esse. Solum summum cancer domi periti forisque locupletem experientiam clinicam habent. Aegri cancer colorectalis auctoritatem per Global Oncologist Network Peritus consultationem adhibere possunt, optimum consilium diagnosis et curationi obtinere.